Shattuck Labs Awaits Q3 2026 Earnings Amid Mixed Analyst Sentiment
Shattuck Labs is expected to report its third-quarter 2026 results on November 10, with analysts forecasting a loss of $0.10 per share and minimal revenue of $30,000. The company met prior EPS expectations but continues to operate at a loss. Despite a recent stock uptick, analyst ratings vary widely, ranging from 'strong-buy' to 'sell,' reflecting uncertainty about its long-term prospects.
Shattuck Labs (STTK) is set to release its third-quarter 2026 earnings on Tuesday, November 10, with analysts forecasting a loss of $0.10 per share and revenue of just $30,000. This follows the company’s prior earnings report on August 11, where it met expectations with a $0.12 loss per share, maintaining its pattern of operating at a deficit despite meeting short-term benchmarks. The stock has seen modest movement, rising $0.10 to $5.42 during midday trading on November 3, though trading volume remained below average at 61,072 shares versus a typical 965,515. Market capitalization stands at $544.47 million, with a negative P/E ratio of -10.64 and a beta of 1.09, indicating moderate volatility relative to the broader market. The company’s 52-week range is $1.72 to $8.33, reflecting significant price swings over time.
The background for this moment lies in Shattuck Labs’ clinical-stage biotechnology focus, particularly its Agonist Redirected Checkpoint (ARC) platform aimed at developing novel immunotherapies for cancer. Its pipeline includes investigational therapies like SL-172154 and SL-173154, which target immune pathways such as CD40 and PD-L1. Despite these scientific ambitions, the company has yet to generate meaningful revenue or profitability. Analyst sentiment is sharply divided: Raymond James and Needham & Company LLC have issued strong-buy ratings with price targets up to $19.00, while Weiss Ratings maintains a “sell (d-)” rating. JPMorgan and UBS also rate the sto
Shattuck Labs’ upcoming earnings report could influence investor confidence in early-stage biotech firms more broadly, particularly those relying on high-risk, long-term R&D without near-term revenue. The mixed analyst outlook reflects a wider market tension between supporting innovation and demanding financial accountability—especially as biotech valuations remain sensitive to clinical milestones and funding cycles. If the company fails to show progress toward profitability or pipeline advancement, it may trigger broader skepticism about similar firms, potentially affecting venture capital flows into early-stage therapeutics. Conversely, if the report hints at positive clinical data or strategic partnerships, it could bolster confidence in biotech innovation despite current losses. A comparable precedent is the 2018 market reaction to CRISPR Therapeutics’ earnings, where a lack of near-term revenue led to volatility despite promising science. What may follow depends on whether Shattuc